Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength. A significant unmet need exists for treatment that is more effective than current therapies and well tolerated, thereby improving patient compliance. We assess how current therapies are differentiated based on the performance of key drug attributes and measure their impact on rheumatologists’ and endocrinologists’ prescribing behavior. We also evaluate the most important unmet needs in the treatment of osteoporosis and discuss the impact of the launch of Evenity on these needs. Our conjoint analysis reveals the trade-offs in key attributes, such as risk of fracture, safety, dosing burden, and price, that surveyed physicians are willing to make when considering new treatment options for osteoporosis.
- What are the treatment drivers and goals for osteoporosis?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do U.S. and European physicians rate the performances of current therapies, including Eli Lilly’s Forteo, Amgen / UCB’s Evenity, Amgen’s Prolia, and Radius Health’s Tymlos, on key treatment drivers and goals?
- How has the launch of Evenity in the United States affected the need for more-efficacious osteoporosis treatments?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European physicians for a hypothetical new osteoporosis drug?
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European rheumatologists and endocrinologists fielded in March 2020
Key companies: Eli Lilly, Amgen, Radius Health, Merck, Novartis
Key drugs: Evenity, Prolia, Forteo, Tymlos
- Osteoporosis - Unmet Need - Detailed, Expanded Analysis (US/EU)
Author(s): Shambhavi Shukla
David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.